BRIEF-IP Says P2b Study Of Leramistat In RA Did Not Meet Primary Endpoint

Reuters

Feb 17

Feb 17 (Reuters) - IP Group PLC IPO.L:

ISTESSO UPDATE ON P2B STUDY OF LERAMISTAT IN RA
STUDY DID NOT MEET PRIMARY ENDPOINT OF IMPROVEMENT IN ACR20 VERSUS PLACEBO
SIGNIFICANT IMPROVEMENTS WERE SEEN IN KEY SECONDARY ENDPOINT
NO NEW SAFETY CONCERNS WERE IDENTIFIED IN STUDY

Source text: ID:nRSQ3274Xa

Further company coverage: IPO.L

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2512566915"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2512566915\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2512566915?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-17 15:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2512566915","market":"us","top_or_hot":-1,"title":"BRIEF-IP Says P2b Study Of Leramistat In RA Did Not Meet Primary Endpoint","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-IP Says P2b Study Of Leramistat In RA Did Not Meet Primary Endpoint </title></head><body><p><span>Feb 17 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/IPZYF\">IP Group PLC</a> <span>IPO.L</span>:</p><ul><li><p>ISTESSO UPDATE ON P2B STUDY OF LERAMISTAT IN RA</p></li><li><p>STUDY DID NOT MEET PRIMARY ENDPOINT OF IMPROVEMENT IN ACR20 VERSUS PLACEBO</p></li><li><p>SIGNIFICANT IMPROVEMENTS WERE SEEN IN KEY SECONDARY ENDPOINT</p></li><li><p>NO NEW SAFETY CONCERNS WERE IDENTIFIED IN STUDY</p></li></ul><p>Source text: <span>ID:nRSQ3274Xa</span></p><p>Further company coverage: <span>IPO.L</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-IP Says P2b Study Of Leramistat In RA Did Not Meet Primary Endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-IP Says P2b Study Of Leramistat In RA Did Not Meet Primary Endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-02-17 15:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-IP Says P2b Study Of Leramistat In RA Did Not Meet Primary Endpoint </title></head><body><p><span>Feb 17 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/IPZYF\">IP Group PLC</a> <span>IPO.L</span>:</p><ul><li><p>ISTESSO UPDATE ON P2B STUDY OF LERAMISTAT IN RA</p></li><li><p>STUDY DID NOT MEET PRIMARY ENDPOINT OF IMPROVEMENT IN ACR20 VERSUS PLACEBO</p></li><li><p>SIGNIFICANT IMPROVEMENTS WERE SEEN IN KEY SECONDARY ENDPOINT</p></li><li><p>NO NEW SAFETY CONCERNS WERE IDENTIFIED IN STUDY</p></li></ul><p>Source text: <span>ID:nRSQ3274Xa</span></p><p>Further company coverage: <span>IPO.L</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPO.UK","symbol_name":"IP GROUP","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250217:nFWN3P800I:1","article_id":"2512566915","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2512566915","pubTimestamp":1739777493,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-IP Says P2b Study Of Leramistat In RA Did Not Meet Primary Endpoint Feb 17 (Reuters) - IP Group PLC IPO.L:ISTESSO UPDATE ON P2B STUDY OF LERAMISTAT IN RASTUDY DID NOT MEET PRIMARY ENDPOINT OF IM","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IPO.UK":"IP GROUP","BK5078":"资产管理与托管银行"},"translate_title":"BRIEF-IP称Leramistat治疗RA的P2b研究未达到主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPO.UK":0.9},"content_text":"BRIEF-IP Says P2b Study Of Leramistat In RA Did Not Meet Primary Endpoint Feb 17 (Reuters) - IP Group PLC IPO.L:ISTESSO UPDATE ON P2B STUDY OF LERAMISTAT IN RASTUDY DID NOT MEET PRIMARY ENDPOINT OF IMPROVEMENT IN ACR20 VERSUS PLACEBOSIGNIFICANT IMPROVEMENTS WERE SEEN IN KEY SECONDARY ENDPOINTNO NEW SAFETY CONCERNS WERE IDENTIFIED IN STUDYSource text: ID:nRSQ3274XaFurther company coverage: IPO.L ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}